1-(6-((三甲基甲硅烷基)乙炔基)吡啶-2-基)乙酮 | 874379-34-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(6-((三甲基甲硅烷基)乙炔基)吡啶-2-基)乙酮
• 英文名称: 1-(6-((trimethylsilyl)ethynyl)pyridin-2-yl)ethanone
• 英文别名: 1-[6-(2-trimethylsilylethynyl)pyridin-2-yl]ethanone
• CAS: 874379-34-7
• 化学式: C₁₂H₁₅NOSi
• 分子量: 217.343
• InChiKey: AAWBDEAPGNSKFN-UHFFFAOYSA-N

物化性质

• 沸点：
  291.6±40.0 °C(Predicted)
• 密度：
  1.01±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.51
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(6-((三甲基甲硅烷基)乙炔基)吡啶-2-基)乙酮 在 bis(triphenylphosphine)palladium(II)-chloride copper(l) iodide 、 四丁基氟化铵 、 二异丙胺 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 1,2-di(6-acetylpyrid-2-yl)ethyne
  参考文献：
  名称：

  Synthetic Approaches to Polypyridyl Bridging Ligands with Proximal Multidentate Binding Sites

  摘要：

  A series of 12 bridging ligands was prepared. These ligands include a central linker appended to two 1,8-naphthyrid-2-yl or two 1,10-phenanthrolin-2-yl units. The linkers include pyridazin-3.6-diyl, 1,8-naphthyrid-2,7-diyl, 2,2'-bipyrid-6,6'-diyl, 1, 10-phenanthrolin-2,9-diyl, 1,2-di(2'-pyrid-6'-yl)ethyne, and 3,6-di(2'-pyrid-6'-yl)pyridazine. The ligands were synthesized from the diacetyl derivative of the central linker by a Friedlander condensation with either 2-aminonicotinaldehyde or 8-amino-7-quinolinecarbaldehyde. The precursor diacetyl derivatives were, in turn, prepared by pathways involving Stille and Sonogashira couplings. Examination of the electronic absorption spectra of the bridging ligands shows the strongest correlation to be between pairs of ligands having the same central linker. Complexation studies will follow.

  DOI：

  10.1021/jo051937r
• 作为产物：
  描述：

  2,6-二溴吡啶 在 bis(triphenylphosphine)palladium(II)-chloride copper(l) iodide 、 正丁基锂 、 二异丙胺 作用下， 以 四氢呋喃 、 乙醚 、 正己烷 为溶剂， 反应 90.0h， 生成 1-(6-((三甲基甲硅烷基)乙炔基)吡啶-2-基)乙酮
  参考文献：
  名称：

  Synthetic Approaches to Polypyridyl Bridging Ligands with Proximal Multidentate Binding Sites

  摘要：

  A series of 12 bridging ligands was prepared. These ligands include a central linker appended to two 1,8-naphthyrid-2-yl or two 1,10-phenanthrolin-2-yl units. The linkers include pyridazin-3.6-diyl, 1,8-naphthyrid-2,7-diyl, 2,2'-bipyrid-6,6'-diyl, 1, 10-phenanthrolin-2,9-diyl, 1,2-di(2'-pyrid-6'-yl)ethyne, and 3,6-di(2'-pyrid-6'-yl)pyridazine. The ligands were synthesized from the diacetyl derivative of the central linker by a Friedlander condensation with either 2-aminonicotinaldehyde or 8-amino-7-quinolinecarbaldehyde. The precursor diacetyl derivatives were, in turn, prepared by pathways involving Stille and Sonogashira couplings. Examination of the electronic absorption spectra of the bridging ligands shows the strongest correlation to be between pairs of ligands having the same central linker. Complexation studies will follow.

  DOI：

  10.1021/jo051937r

文献信息

• [EN] RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF<br/>[FR] INHIBITEURS DE RET, COMPOSITIONS PHARMACEUTIQUES ET UTILISATIONS ASSOCIÉES
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2020114487A1

  公开（公告）日：2020-06-11

  Provided herein are a RET inhibitor, a pharmaceutical composition thereof and uses thereof. In particular, provided is a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Provided is a pharmaceutical composition comprising the compound, and uses of the compound and pharmaceutical composition thereof for the preparation of a medicament, in particular for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.

  本文提供了一种RET抑制剂，其药物组合物以及其用途。具体而言，提供了具有化学式（I）或其立体异构体、几何异构体、互变异构体、N-氧化物、溶剂合物、代谢物、药用可接受盐或其前药的化合物。提供了包括该化合物的药物组合物，并且提供了该化合物及其药物组合物的用途，用于制备药物，特别是用于治疗和预防与RET相关的疾病和症状，包括癌症、肠易激综合征以及/或与肠易激综合征相关的疼痛。
• [EN] HYDRAZNE DERIVATIVES FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS D'HYDRAZINE POUR LE TRAITEMENT DU CANCER
  申请人：UNIV RUTGERS

  公开号：WO2016123253A1

  公开（公告）日：2016-08-04

  The invention provides compounds of formula (I): and salts thereof, wherein ring A, R2, HET, X, n, and R3 have any of the meanings described in the specification, as well as compositions comprising such compounds and salts, and methods for treating cancer using such compounds and salts.

  该发明提供了式（I）的化合物及其盐，其中环A、R2、HET、X、n和R3具有规范中描述的任何含义，以及包含这些化合物和盐的组合物，以及使用这些化合物和盐治疗癌症的方法。
• Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders
  申请人：MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

  公开号：US09079853B2

  公开（公告）日：2015-07-14

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of degenerative diseases and disorders.

  本文提供的化合物具有以下公式（I）： 其中取代基如规范中所披露的那样，以及其药学上可接受的盐。这些化合物以及含有它们的药物组合物，对于治疗退行性疾病和疾患是有用的。
• Isatin Compounds, Compositions And Methods For Treatment Of Degenerative Diseases And Disorders
  申请人：MUSC Foundation For Research Development

  公开号：US20150218128A1

  公开（公告）日：2015-08-06

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of degenerative diseases and disorders.

  本文提供的是公式(I)的化合物，以及其药学上可接受的盐，其中取代基如规范中所述。这些化合物及含有它们的药物组合物，可用于治疗退行性疾病和疾病。
• US2014/275075
  申请人：——

  公开号：——

  公开（公告）日：——